Cornell University

The United States of America As Represented by the Department of Health

Genvec, Inc.

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Memorial Sloan Kettering Cancer Center

Universitéde Strasbourg

Assistance Publique - Hopitaux De Paris (aphp)

The United States of America, As Represented by the Secretary, Department of Health and Human Services

The State University of New York

Transgene S.a.

Hospital for Special Surgery

Cooper Laboratories, Inc.

Université Paris Sud Xi

Ronald G Crystal

Todd K Rosengart

Stephen Kaminsky

Martin J Hicks

Imre Kovesdi

Erik S Falck-Pedersen

Odelya E Pagovich

Neil R Hackett

Katie Stiles

Jonathan B Rosenberg

Bishnu P De

Thomas J Wickham

Patrick Aubourg

Jason Gall

Viviane Tabar

Helene Monique Puccio

Pierre Bougneres

Maria J Chiuchiolo

Michel Perricaudet

Raymond A Hartman

Stephen E Epstein

Andrea Pavirani

Leslie Stratford-Perricaudet

Wilfried Dalemans

Toren Finkel

Dolan Sondhi

Megumi Mathison

Julie L Boyer

Robin L Davisson

Xiaohuai Zhou

Philip L Leopold

Noboru Sato

Nicolaas J Roosdorp

Karil Abrahamson

Kunihiko Yoshimura

Andrea Mastrangeli

Melissa Rosenfeld

Prem Seth

Yadi Tan

Christopher J Magovern

Meredith Sosulski

Jonathan Rosenberg

Robert Gersch

Bishnu De

Arash Rafii Tabrizi

Chisa Hidaka

Oheneba Boachie-Adjei

Bernard A Rawlins

Raul G Guzman

Stephen M Kaminsky

Compositions and methods for eosinophilia in a mammal are provided. In one embodiment, the composition is a viral gene therapy vector, and a single dose of the vector reduces increased numbers of eosinophils in a mammal.

Gene therapy for eosinophilic disorders

The invention provides methods to inhibit or treat brain cancers by locally inhibiting expression or activity of growth factors or growth factor receptors.

Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies

A gene therapy treatment for alpha 1-antitrypsin (AAT) deficiency is provided comprising a plasmid or viral, e.g., an AAV, vector coding for an elastase- or cathepsin G-inhibiting, oxidation-resistant human AAT with a substitution at, for example, Met358 and/or Met351.

Oxidation-resistant AAT gene therapy

Modified AAV vectors and uses thereof are provided.

Genetic modification of the AAV capsid resulting in altered tropism and enhanced vector delivery

The invention provides a method of treating ovarian cancer in a patient by administering to the patient an adeno-associated virus (AAV) vector encoding an anti-VEGF antibody or antigen binding fragment thereof.

Adenoassociated viral mediated persistant anti-VEGF therapy for ovarian cancer

Provided is a method of treating coronary artery disease in a mammal, comprising administering to a region of the heart of the mammal (a) a first vector encoding one or more angiogenic proteins which induce vascularization in the heart of the mammal, and (b) a second vector encoding one or more cardio-differentiating transcription factors which induce the production of induced cardiomyocytes (iCM) in the heart of the mammal, whereby the coronary artery disease in the mammal is treated. In a preferred embodiment, the first vector is an adenoviral vector encoding VEGF and the second vector is a lentiviral vector encoding Gata4, Mef2c, and Tbx5 (GMT).

Angiogenic conditioning to enhance cardiac cellular reprogramming of fibroblasts of the infarcted myocardium

A method for preventing or treating cardiomyopathy due to energy failure in a subject in need thereof is provided. The method comprises administering to the subject a therapeutically effective amount of a vector which comprises a nucleic acid sequence encoding a gene that can reverse energy failure. An exemplary cardiomyopathy is that which is associated with Friedreich ataxia and an exemplary nucleic acid sequence comprises a nucleic acid that encodes frataxin (FXN).

Methods and pharmaceutical compositions for the treatment and the prevention of cardiomyopathy due to Friedreich ataxia

This invention is directed to a vector which comprises a promoter operably linked to a nucleic acid sequence encoding a therapeutic gene that blocks allergic reactions. The invention is also directed to a composition comprising the vector and method of using the vector to reduce or inhibit an immune response or allergic reaction to an allergen in a mammal.

Gene therapy to prevent reactions to allergens

This invention is directed to a vector which comprises a promoter operably linked to a nucleic acid sequence encoding the human C1 esterase inhibitor or Factor XII. The invention is also directed to a composition comprising the vector and a method of using the vector to treat or prevent hereditary angioedema.

Adeno-associated virus mediated delivery of C1E1 as a therapy for angioedema

The invention is directed to an adeno-associated virus (AAV) vector which comprises a nucleic acid sequence encoding an antibody or antigen binding fragment that binds to nicotine or a nicotine analog. The invention also is directed to a composition comprising the AAV vector and methods of using the AAV vector to induce an immune response against nicotine in a mammal.

AAV-directed persistent expression of an anti-nicotine antibody gene for smoking cessation

The invention is directed to a conjugate which comprises an isolated adenovirus hexon protein coupled to nicotine or a nicotine analog, as well as a method of inducing an immune response against nicotine in a human by using the conjugate.

Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction

The invention is directed to an adenovirus-antigen conjugate comprising (a) a disrupted adenovirus with a coat protein and (b) an antigen conjugated to the coat protein of the disrupted adenovirus, as well as a conjugate comprising (a) a disrupted adenovirus with a coat protein and (b) an antigen conjugated to the coat protein of the disrupted adenovirus. The invention also provides a method of inducing an immune response against an antigen in a human using the aforementioned conjugates. The invention further provides an adeno-associated viral vector comprising a nucleic acid sequence which encodes an antibody directed against cocaine.

Disrupted adenovirus-based vaccine against drugs of abuse

Methods and pharmaceutical compositions for the treatment of cardiomyopathy due to friedreich ataxia

The invention provides a gene transfer vector for inducing an immune response againstin a mammal. The gene transfer vector comprises a nucleic acid sequence encoding an immunogenic portion of one or more proteins ofand/or a nucleic acid sequence encoding a monoclonal antibody directed against. The invention further provides a method of producing an immune response againstin a mammal comprising administration of the gene transfer vector to the mammal. The invention also provides a monoclonal antibody directed against the Virulence (V) antigen of, as well as a hybridoma cell line producing same and a nucleic acid sequence encoding same.

[object Object]

Growing community of inventors

New York, NY, United States of America

Ronald G Crystal